Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Bayer Ag ADR (OP:BAYRY)

11.76 -0.03 (-0.25%)
Streaming Delayed Price Updated: 9:59 AM EDT, Apr 10, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Bayer Ag ADR

< Previous 1 2 3 4 5 6 7 Next >
News headline image
USDA Stuns Markets as April WASDE Raises Farm Gate Prices Amid Domestic Supply Crunch
The United States Department of Agriculture (USDA) sent shockwaves through the agricultural sector this morning with the release of the April 2026 World Agricultural Supply and Demand Estimates (WASDE)... 
Via MarketMinute
Topics Economy Energy
News headline image
The Great Unbundling: How AI’s Insatiable Hunger is Driving a Corporate Divestiture Gold Rush
As of March 18, 2026, the corporate landscape has undergone a radical transformation. The era of the sprawling global conglomerate, once the gold standard of industrial stability, is rapidly giving way... 
Via MarketMinute
Topics Artificial Intelligence Economy
Bayer Stock Fuels Hyper Bullish Retail Mood After Confirming New Stroke Study Met Key Goals Following 2023 Halt ↗
Via Stocktwits
News headline image
The Section 122 Pivot: How a 10% Global Tariff is Reshaping the 2026 Market Landscape
The global financial markets have entered a period of profound "legalized volatility" following the White House’s emergency invocation of Section 122 of the Trade Act of 1974. This move, triggered by a... 
Via MarketMinute
Topics Economy Electric Vehicles Government
News headline image
The Strategic Crossroads of FMC Corporation: A 2026 Research Deep Dive
Date: March 3, 2026 Introduction FMC Corporation (NYSE: FMC) currently finds itself at one of the most pivotal junctures in its 140-year history. Once a darling of the agricultural sector known for its... 
Via Finterra
Topics Economy Intellectual Property World Trade
News headline image
The Great Grain Pivot: USDA Forecasts Record Soy Surge as Corn Retreats in 2026
The American agricultural landscape is undergoing a massive structural shift as the 2026 planting season approaches. According to the U.S. Department of Agriculture's (USDA) 102nd Agricultural Outlook... 
Via MarketMinute
Topics Energy
News headline image
European Commission Grants Marketing Authorization to Cytokinetics for Cardiac Drug MYQORZO
In a landmark decision for the cardiovascular treatment landscape, the European Commission (EC) officially granted marketing authorization to Cytokinetics, Inc. (Nasdaq: CYTK) on February 17, 2026, for... 
Via MarketMinute
Topics Intellectual Property
News headline image
Bayer's $7.25 Billion Roundup Settlement: A 21-Year Plan for Certainty
Bayer AG (OTC: BAYRY) has announced a sweeping $7.25 billion proposed class action settlement aimed at resolving the vast majority of its remaining U.S. litigation involving the weedkiller Roundup.... 
Via MarketMinute
Topics Lawsuit
News headline image
Uncle Sam’s $44.36 Per Acre Gamble: How Government Intervention is Distorting the 2026 Planting Season
As the 2026 planting season approaches, American farmers are facing a paradox of record-low commodity prices and unprecedented government support. The centerpiece of this intervention is the newly... 
Via MarketMinute
Topics Economy
News headline image
German Pharma Giant Bayer Proposes $7.25 Billion Settlement Over Monsanto's Roundup Cancer Claims In US ↗
Bayer AG (OTC: BAYRY) on Tuesday proposed a $7.25 billion settlement to resolve thousands of U.S. lawsuits claiming that its weedkiller Roundup causes cancer. The product was originally made by... 
Via Benzinga
Topics Lawsuit
News headline image
Retina’s ‘Sustained’ Moment: Ocular Therapeutix Braces for Game-Changing Phase 3 AXPAXLI Data
The multi-billion dollar wet Age-Related Macular Degeneration (wet AMD) market is standing on the precipice of a transformative shift. Today, February 16, 2026, Ocular Therapeutix (NASDAQ: OCUL) is in... 
Via MarketMinute
News headline image
Wall Street’s ‘Fear Gauge’ Reclaims the 20 Mark: Why the Greenland Tariff Threat and Earnings Redlining Triggered a Market Reset
The CBOE Volatility Index (VIX), often hailed as the stock market’s “fear gauge,” surged past the critical 20.00 threshold on January 20, 2026, marking a significant shift in investor sentiment as the... 
Via MarketMinute
Topics Economy Government Stocks
News headline image
The mRNA 2.0 Inflection: A Deep Dive into Moderna (MRNA) as it Faces a Critical 2026
As of January 16, 2026, Moderna, Inc. (NASDAQ: MRNA) stands at a critical crossroads. Once the poster child for the biotechnology industry’s rapid response to a global pandemic, the Cambridge-based... 
Via Finterra
Topics Initial Public Offering Intellectual Property Lawsuit
News headline image
Beyond the Bailout: US Farm Groups Demand Structural Reform as USDA Unveils $12 Billion 'Bridge' Program
As the 2026 calendar year begins, the United States agricultural sector finds itself at a critical policy crossroads. On one hand, the U.S. Department of Agriculture (USDA) has just finalized the... 
Via MarketMinute
Topics Economy Energy
News headline image
FDA Signs Off On Bayer's New Lung Cancer Drug — Early Results Look Promising ↗
FDA grants accelerated approval to Bayer's Hyrnuo and full approval to Amgen's Imdelltra, expanding treatment options for advanced lung cancer. 
Via Benzinga
News headline image
Siemens Warns Currency Headwinds Will Hit 2026 Results; CEO Defends Mid-Term Target ↗
 
Via Benzinga
News headline image
Daré Bioscience (DARE) Q3 2025 Earnings Transcript ↗
Daré Bioscience (DARE) Q3 2025 Earnings Transcript 
Via The Motley Fool
News headline image
Agricultural Conglomerate Bayer Confident In Long-Term Outlook Despite Litigation Risks ↗
Bayer's Q3 earnings rose on strong Crop Science and Pharma sales, with CEO Bill Anderson confident in meeting the company's upgraded 2025 guidance. 
Via Benzinga
News headline image
Top 3 Health Care Stocks You'll Regret Missing In October ↗
 
Via Benzinga
News headline image
Exelixis Stock Falls After Phase 3 Colorectal Cancer Trial Shows Mixed Results ↗
Exelixis stock dips after Phase 3 data show modest survival gains from zanzalintinib and Tecentriq combo in colorectal cancer patients. 
Via Benzinga
News headline image
Agri-Science Giant Corteva Eyes Breakup To Shield Seed Unit From Future Risks: Report ↗
Corteva is exploring a breakup that would separate its seed and pesticide businesses. The move could reshape agriculture amid falling crop prices and rising costs. 
Via Benzinga
News headline image
Retail Turns Bearish On Bayer After $1.3B Kumquat Cancer Drug Deal ↗
Bayer and Kumquat Biosciences have signed an exclusive global license and collaboration to develop a KRAS G12D inhibitor, with potential milestone payments of up to $1.3 billion 
Via Stocktwits
News headline image
U.S. Current-Account Deficit Widens to $450 Billion Amid Trade Imbalances and Energy Imports
The United States current-account deficit expanded sharply to $450 billion in the first half of 2025, marking a renewed widening of the country's financial shortfall with the rest of the world. This... 
Via MarketMinute
Topics Artificial Intelligence Economy Supply Chain
News headline image
History of Recursion Pharmaceuticals, Inc.: AI‑Driven Drug Discovery Beginnings (NASDAQ:RXRX)
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) emerged in the 2010s as one of the pioneers in leveraging artificial intelligence (AI) and advanced data analytics to transform drug discovery and... 
Via MarketMinute
Topics Artificial Intelligence
News headline image
Exelixis' Zanzalintinib Combo Boosts Survival In Colorectal Cancer, Stock Soars ↗
Exelixis' STELLAR-303 trial shows zanzalintinib plus Tecentriq improved survival in colorectal cancer, with no new safety concerns reported. 
Via Benzinga
News headline image
Exelixis Catapults 14% On Positive Results For Next-Gen Colon Cancer Drug ↗
Shares surged Monday after the company said its next-generation cancer drug showed promise in a colon cancer study. 
Via Investor's Business Daily
News headline image
Bayer Profit Drops 35%, Launches Overhaul To Counter Generic Pressure ↗
Bayer Q1 profit declined to $1.45 billion, but earnings and sales topped estimates as pharma growth offset crop science headwinds and currency impacts. 
Via Benzinga
News headline image
FDA Grants Complete Approval To Bayer's Drug For Certain Type Cancer With Mutation ↗
Bayer's Vitrakvi receives full FDA approval based on solid tumor data showing sustained efficacy in NTRK fusion-positive patients. 
Via Benzinga
News headline image
Bayer Enters License Agreement With China’s Puhe BioPharma For Cancer Drug Candidate: Retail Stays Bullish ↗
Bayer’s Pharmaceuticals Division’s Head of Business Development and Licensing Juergen Eckhardt said the drug’s “highly selective targeting” of cancer cells while sparing healthy ones is “very... 
Via Stocktwits
News headline image
Bayer CEO: 2025 Will Be 'Most Difficult' Year In Turnaround Plan, Expects Improved Performance From 2026 Onwards ↗
Bayer reported Q4 adjusted EPS of $0.28, missing estimates, but sales beat forecasts. The company sees 2025 as a tough year, with growth expected from 2026. 
Via Benzinga
Topics Earnings
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.